/Companies

Anto Biosciences

YC F25

San Francisco, US · Founded 2025 · 4 employees · 11 known investors

Find your way into Anto Biosciences

Sign up to see every warm intro you have to Anto Biosciences

  • Paths you didn't know you had: your email and LinkedIn already hold routes to the Anto Biosciences team. We find them for you
  • 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
  • Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone

Days of research, done the moment you sign in, with every route ranked by how warm it is.

Anto is an AI research lab developing foundation models for microbial communities to enable precision medicine by computationally modeling how the microbiome affects individual drug response. The company serves pharmaceutical and clinical research by combining AI with genomic and microbiome data.

Also known as Anto

Founders & leadership· Y Combinator alumni (F25)

Anto Biosciences was founded in 2025 by Arvid E. Gollwitzer and David de Gruijl.

AEArvid E. Gollwitzer
Arvid E. GollwitzerFounder/CEOArvid E. Gollwitzer is a researcher with experience at the Broad Institute, Harvard, and MIT, and has held a lecturer position at ETH Zurich. He is the founder of Anto Biosciences.
DDDavid de Gruijl
David de GruijlFounder/CTODavid de Gruijl is a co-founder of Anto Biosciences with prior experience at Janssen Pharmaceuticals and research affiliations with ETH Zurich and the Gastroenterology Department at Brigham and Women's Hospital, Harvard Medical School.

Investors · 11

The YC application· Fall 2025 batch

Anto Biosciences - YC F25 - Launch Video

Arvid E. Gollwitzer

Related companies · 8

Octant BioOctant is a therapeutics company that develops small molecule drugs to treat protein misfolding diseases. Using synthetic biology, high-throughput chemistry, and AI/ML, the company's Navigator platform studies how target proteins interact within living human cells to enable drug discovery for rare diseases and oncology.
Talus BioTalus develops a proprietary platform that measures and modulates the regulome—the body's gene expression control system—in native cellular contexts. The company designs AI-driven compounds and uses functional proteomics to enable drug discovery for transcription factors and regulatory proteins implicated in oncology, rare disease, and immune dysfunction.
Arpeggio BioArpeggio Bio is a pharmaceutical company that uses AI and high-throughput RNA-sequencing to develop drugs targeting transcription factors, including historically "undruggable" proteins such as NRF2, TEAD, and GPX4. Its lead program targets IO-resistant melanoma, and it has worked on rare disease and inflammation programs through partnerships.
Sequence BioSequence Bio works on drug target discovery, using the Newfoundland founder effect to identify genetic signals of disease and improve the success rate of drug development.
Kernal BiologicsKernal Bio is a synthetic biology company developing selective mRNA drugs to treat serious illnesses, with a focus on cancer therapeutics and improving patient outcomes.
Intuitive BiosciencesIntuitive Bio develops Colony Surveillance Assays (CSA), diagnostic kits for screening laboratory animal colonies for exposure to specific pathogens. The kits are designed for research institutions and breeding facilities requiring pathogen-free colony verification.
Helix NanotechnologiesHelixNano develops an mRNA platform aimed at applications including cancer treatment, COVID-19 vaccines, and environmental interventions. The company is working on a COVID-19 vaccine candidate for immunocompromised patients and other mRNA-based technologies.
Engage BioEngageBio develops DNA-based medicines using proprietary non-viral delivery technology to achieve extended therapeutic expression from a single dose with low manufacturing complexity.

Companies working in the same space as Anto Biosciences.

Legal entities · 1

corporate structure
Anto Biosciences, Inc.

In the news

Frequently asked questions

What does Anto Biosciences do?
Anto is an AI research lab developing foundation models for microbial communities to enable precision medicine by computationally modeling how the microbiome affects individual drug response. The company serves pharmaceutical and clinical research by combining AI with genomic and microbiome data.
Who founded Anto Biosciences?
Anto Biosciences was founded by Arvid E. Gollwitzer, David de Gruijl in 2025.
Who are Anto Biosciences's investors?
Anto Biosciences's investors include Ritual Capital, RRE Ventures, Y Combinator, 007 Venture Partners, C10 Labs, Demos Strategic Investing Partners, FAST — by GETTYLAB, Massive Tech Ventures and 3 more.
Where is Anto Biosciences headquartered?
Anto Biosciences is headquartered in San Francisco, US.